Showcasing research from the groups of Profs. C. Ortiz Mellet, C. Tros de Ilarduya, and J. M. García Fernández, Universities of Sevilla, Navarra, and the CSIC (Institute of Chemical Research), Spain.

Trehalose-based Siamese twin amphiphiles with tunable self-assembling, DNA nanocomplexing and gene delivery properties

The disaccharide trehalose is a geminated scaffold suitable for the synthesis of molecularly defined conjoined (“Siamese”) twin amphiphiles capable of condensing DNA into transfectious nanocomplexes; depending on the architectural properties, diverse topologies can be programmed resulting in selective in vivo tropisms.

As featured in:

See Concepción Tros de Ilarduya, Carmen Ortiz Mellet, José M. García Fernández et al., Chem. Commun., 2019, 55, 8227.
Trehalose-based Siamese twin amphiphiles with tunable self-assembling, DNA nanocomplexing and gene delivery properties†

Ana I. Carbajo-Gordillo, Julio Rodríguez-Lavado, José Luis Jiménez Blanco, Juan M. Benito, Christophe Di Giorgio, Concepción Tros de Ilarduya, Carmen Ortiz Mellet and José M. García Fernández

An original family of multivalent vectors encompassing gemini and facial amphiphilicity, namely cationic Siamese twin surfactants, has been prepared from the disaccharide trehalose; molecular engineering lets us modulate the self-assembling properties and the topology of the nanocomplexes with plasmid DNA for efficient gene delivery in vitro and in vivo.

The approval of several gene therapy treatments by regulatory agencies and the promising results obtained in recent clinical trials in areas like cancer, epilepsies, hemophilia, retinal degeneration, Parkinson’s disease or metabolic disorders have strongly nurtured expectations of a new age for personalized medicine. The main hurdle for these channels is the lack of delivery vectors capable of efficiently and safely transporting the therapeutic gene material to enforce the desired genetic change in the target cells. Despite great progress, viral systems still raise concerns about immunogenicity, random integration in the host genome, limited DNA packaging capacity and the cost of clinical grade production of large batches. Non-viral carriers have the potential to address most of these limitations and some are currently being applied in a number of clinical trials. However, most of them are intrinsically polydisperse in nature, e.g., cationic polymers, lack conformational definition (e.g., cationic dendrimers) and/or require multicomponent formulation (e.g., cationic lipids), which hampers precise structure–efficiency relationship and optimization studies. Cationic multivalent surfactants with well-defined molecular structures, among which cyclodextrin (CD) derivatives are archetypal examples, epitomize remarkable exceptions. Their giant amphiphilic surface exposes facially segregated cationic and lipophilic domains that concertedly drive co-assembly with nucleic acids; however, keeping diastereomeric purity can be significantly demanding. This problem is largely mitigated for the cationic lipid dimers generically termed gemini surfactants, the smallest representatives of multivalent amphiphiles. Gemini surfactants have proven to be superior to their monomeric counterparts as gene vectors, but unlike their rigid high-valent facial amphiphilic homologues they generally require a helper lipid to accomplish the task. Most importantly, the topological properties and stability of multivalent and gemini-based supramolecular aggregates exhibit a strong dependence on vector structure and local pH, enabling control over cell uptake and cargo release. Here we report that the disaccharide \( \alpha,\alpha'-\text{trehalose} \), a \( C_2 \)-symmetrical glucose dimer, can be engineered through modular “click” strategies to access “Siamese twin” surfactants amalgamating the advantages of gemini and facial amphiphilicity for efficient DNA nanocomplexation and delivery in vitro and in vivo.

The structure/activity relationship data collected during the last decade for cyclooligosaccharide-based gene delivery systems indicate that facially differentiated constructs consisting

---

† Electronic supplementary information (ESI) available: Experimental details (synthesis, nanoparticle characterization, in vitro and in vivo transfection) and copies of the NMR spectra of the new compounds. See DOI: 10.1039/c9cc04489b

‡ These authors contribute equally.
of monosaccharide units bearing hexanoyl chains at secondary positions and a bifurcated presentation of amino groups at the primary position are particularly favorable. This combination of functional elements provides an appropriate hydrophilic/hydrophobic balance and an optimal density of cationizable centers for efficient interaction with the polyphosphate backbone in the nucleic acid partner. We capitalized on this background to develop a set of new trehalose-based Siamese twin prototypes 6–10 (Scheme 1). The rationale is that specific arrangements of flexible spacers (cysteaminy1, ethylene segments), pH buffering groups (triazole heterocycles, tertiary amines), hydrogen bonding modules (thiourea motifs) and peripheral primary amines can translate into distinct self-assembling properties, plasmid DNA (pDNA) complexing abilities and vector/pDNA nanocomplex topologies, thereby impacting transfection capabilities and providing information on the molecular determinants of efficient gene delivery.

The target gemini facial surfactants 6–10 were synthesized from the 6,6'-diazido-, 6,6'-di-(2-aminoethylthio)- or 6,6'-di-(2-azidoethylthio)-3,3'-trehalose derivatives 1–3 and the alkyne- or isothiocyanate-armed partners 4 and 5 through copper(i)-catalyzed azide-alkyne coupling (CuAAC) and thiourea-forming “click” reactions, respectively (Scheme 1 and ESI†). Their capacity to complex and protect pDNA was initially investigated by electrophoresis mobility shift assay (EMSA) in polyacrylamide gel, using the intercalating agent GelRed® for visualization. Trehalose vector/pDNA formulations were prepared at protonatable nitrogen/anionic phosphate (N/P) ratios of 5, 10 and 20. In all cases, full pDNA complexation, compaction, and protection was achieved, as inferred from the capacity of the compounds to arrest migration of pDNA in the gel, the inability of the fluorescent intercalating agent GelRed® to access the pDNA cargo in the complexes and the recovery of the essentially unaltered pDNA after DNase I/sodium dodecylsulfate (SDS) treatment (Fig. 2B). However, compounds 6 at N/P 5 and 10 and 9 at N/P 5 did not provide stable colloidal suspensions under the conditions used for nanocomplex formulation (Tables S1–S3, ESI†). To ensure a uniform regime, N/P 20 formulations were employed for comparative studies of molecular structure/self-assembly/pDNA nanocomplex topology/gene delivery efficiency relationships.

Compound 6, featuring a rigid triazole moiety connecting the disaccharide core and the cationic arms, afforded stable homogeneous nanospheres of 15 nm diameter (TEM) in aqueous media, a typical behavior of “conical” surfactants. In the presence of pDNA, morula-like nanospheres of 120–140 nm diameter were formed, suggesting that interaction of the intact vector nanospheres with the polyphosphate chain drives compaction of the plasmid (Fig. 3A and B; left panel). Under identical conditions, the homologous derivative 7 afforded 50 nm vesicles that, upon co-formulation with pDNA, reorganized into spherical nanoparticles (80–100 nm in diameter) exhibiting an alternating arrangement of glycolipid bilayers and plasmid chains (Fig. 3A and B; middle panel). The insertion of a flexible cysteaminy1 spacer between the trehalose scaffold and the cationic antennae in compounds 8–10 drastically reduced the predisposition to form defined self-assembled aggregates. In the presence of pDNA, 8 and 9 afforded spherical nanocomplexes similar in size and ultrathin structure to those obtained from 7. Compound 10 exhibited a singular behavior: neat samples showed the presence of bilayer structures characteristic of tubular shaped amphiphiles, whereas in co-formulation with pDNA spherical core-shell nanoparticles (70–80 nm diameter) with a variable level of internal order were formed (Fig. 3A and B; right panel). This scenario strongly suggests a biomimetic two-step mechanism analogous to that characterizing the co-assembly of enveloped viruses: first, the “en masse” interaction of individual molecules of 10 with the nucleic acid takes place and then the external unilamellar shell of the amphiphile forms. Nanostructures of such a type have been previously assembled by sophisticated multiformulation strategies and found to be particularly efficient for nucleic acid cargo delivery to target cells.

Dynamic light scattering (DLS) and mixed mode measurement phase analysis light scattering (M3-PALS) provided hydrodynamic
The transfection efficiency of the Siamese twin vectors 6–10 was initially assessed in COS-7 primate epithelial kidney cells and HepG2 human hepatocarcinoma cells. PEI and the CD-based vector ADM70 (Fig. S15, ESI†), one of the most efficient multivalent molecular vectors reported to date,18 as well as naked pDNA (luciferase encoding), were used as positive and negative controls, respectively (Fig. 4A). Formulations prepared from 7 or 10 at N/P 20 were clearly superior to those elaborated from 6 or 9, having identical numbers of cationic centers, in both cell lineages, spotlighting the aminoethylioureaido motif as a preferred functional element in multivalent gene delivery system prototypes. The 10/pDNA nanocomplexes were the most efficient in these experimental settings, promoting 10- and 1.2-fold higher levels of luciferase expression as compared to bPEI in COS-7 and HepG2 cells, respectively. They also rivalled the transfection proficiency of ADM70/pDNA complexes. Compound 10 further compared favorably with PEI and Lipofectamine 3000† (a commercial cationic lipid formulation) in murine embryonic hepatocyte BNL-CL2 and macrophage RAW 264.7 cells, which are notably more resistant to transfection. Only ADM70 in BNL-CL2 cells was superior. Importantly, irrespective of the trehalose-based vector structure, all the pDNA formulations showed low cytotoxicities (Alamar blue® and MTT cell viabilities >80% and >70%, respectively, except for 6; Fig. S16A and B, ESI†). The best performing vector 10 was next assessed for its ability to complex the plasmid pCMVIL12, which encodes the potent antitumoral cytokine interleukin-12 (IL-12),19 and deliver it into HepG2 cells. The corresponding nanocomplexes (N/P 20) performed about 30% better than bPEI in this assay (Fig. 4B).

The possibility of molding the topological properties at the nanoscale level by acting on the molecular structure of the vector offers unique opportunities to affect the tropism of the nanoparticles in vivo. To explore this issue, nanocomplexes formulated with 8 (spherical multilayered) or 10 (spherical core–shell) at N/P 20 were next injected systemically into mice, and their activity was compared with PBS and the naked DNA as negative controls. The results, based on the luciferase reporter gene expression, indicated that 24 h after the intravenous administration, transfection occurred mainly in the liver in the case of 8, which is consistent with previous data for CD-based vectors affording nanocomplexes with similar topology.6 In sharp contrast, compound 10 promoted transfection in the lung (Fig. 4B), an important target in gene therapy,20 with negligible luminescence detected in other organs,
highlighting the potential of nanocomplex topology control through molecular vector tailoring for tissue-specific gene delivery.

Polyplexes obtained with bPEI exhibited 100% mortality in this assay, whereas all mice survived treatment with formulations containing the trehalose-based Siamese twin amphifilms. Taken together, the results provide a testable prototype to guide future molecular vector design.

The authors thank MINECO/MCIU (SAF2016-76083-R, CTQ2015-64425-C2-1-R, CTQ2015-64425-C2-2-R, RTI2018-097609-B-C21 and RTI2018-097609-B-C22), the Junta de Andalucía (FQM2012-1467), the RTI2018-097609-B-C21 and the IL-12-encoding plasmid pCMV-interleukin-12 (B), at N/P 20 in the presence of 10% fetal bovine serum (FBS). Data obtained with bPEI polyplexes, ADM70, Lipofectamine 3000 and naked pDNA are included for comparison. The data represent the mean ± SD of three wells and are representative of three independent determinations. (C) Gene expression conducted in vivo after intravenous administration of 60 mg of pCMV-Luc VR1216 formulated with 8 or 10 at N/P 20 in the presence of 10% FBS. Bars represent the mean ± SD (n = 7 animals).

Fig. 4 Transfection efficiency in COS-7, HepG2, BNL-CL2 and RAW 246.7 cells for nanocomplexes formulated with 6–10 and the luciferase-encoding gene pCMV-Luc VR1216 (A), and in HepG2 cells for formulations with 10 and the IL-12-encoding plasmid pCMV-interleukin-12 (B), at N/P 20, in the presence of 10% fetal bovine serum (FBS). Data obtained with bPEI polyplexes, ADM70, Lipofectamine 3000 and naked pDNA are included for comparison. The data represent the mean ± SD of three wells and are representative of three independent determinations. (C) Gene expression conducted in vivo after intravenous administration of 60 mg of pCMV-Luc VR1216 formulated with 8 or 10 at N/P 20 in the presence of 10% FBS. Bars represent the mean ± SD (n = 7 animals).

Conflicts of interest

There are no conflicts to declare.

Notes and references

1 (a) E. Bender, *Nature*, 2016, 537, S57; (b) Blits and H. Petry, *Front. Neuroanat.*, 2017, 10, 128; (c) S. L. Ginn, A. K. Amaya, I. E. Alexander, M. Edelstein and M. R. Abedi, *J. Gene Med.*, 2018, 10, 128; (d) N. Matharu, S. Rattanasoph, S. Tamura, L. Maliskova, W. Wang, A. Bernard, A. Hardin, W. L. Eckalbar, C. Vaisse and N. Ahiutv, *Science*, 2019, 363, eaau0629.

2 P. Colella, G. Ronzitti and F. Mingozi, *Mol. Ther.–Methods Clin. Dev.*, 2018, 8, 87.

3 (a) M. Zeng, D. Zhou, F. Alshehri, I. Lara-Sáez, Y. Lyu, J. Creagh-Flynn, Q. Xu, A. Sigen, J. Zhang and W. Wang, *Nano Lett.*, 2019, 19, 381; (b) F. Wang, J. Gao, J. Xiao and J. Du., *Nano Lett.*, 2018, 18, 5362; (c) S. Liu, D. Zhou, J. Yang, H. Zhou, J. Chen and T. Guo, *J. Am. Chem. Soc.*, 2017, 139, 5102.

4 (a) I. Lostalé-Seijo and J. Montenegro, *Nat. Rev. Chem.*, 2018, 2, 258; (b) C. Chen, Z. Yang and X. Tang, *Med. Res. Rev.*, 2018, 38, 829.

5 (a) E. Junquera and E. Aicart, *Adv. Colloid Interface Sci.*, 2016, 233, 161; (b) J. L. Jiménez Blanco, J. M. Benito, C. Ortiz Mellet and J. M. García Fernández, *J. Drug Delivery Sci. Technol.*, 2017, 42, 18; (c) J. M. García Fernández, J. M. Benito and C. Ortiz Mellet, *Pure Appl. Chem.*, 2013, 85, 1825.

6 (a) C. Ortiz Mellet, J. M. García Fernández and J. M. Benito, *Chem. Soc. Rev.*, 2011, 40, 1586; (b) D. Manzanares, I. Araya-Durán, L. Gallego-Yerga, P. Játiva, V. Márquez-Miranda, J. Canan, J. L. Jiménez Blanco, C. Ortiz Mellet, F. D. González-Nilo, J. M. García Fernández and V. Cenà, *Nanomedicine*, 2017, 12, 1607; (c) X. Zhou, P. Pathak and J. Jayaweekara Rahaj, *Chem. Commun.*, 2018, 54, 11668; (d) R. P. Singh, T. Hidalgo, P.-A. Cazade, R. Darcy, M. F. Cronin, I. Dorin, C. M. O’Driscoll and D. Thompson, *Mol. Pharmaceutics*, 2019, 16, 1358.

7 L. Gallego-Yerga, J. M. Benito, L. Blanco-Fernández, M. Martínez-Negro, I. Vélez, E. Aicart, E. Junquera, C. Ortiz Mellet, C. Tros de Ildaruya and J. M. García Fernández, *Chem. – Eur. J.*, 2018, 24, 8565.

8 B. E. Brycki, I. H. Kowalczyk, A. Szule, O. Kaczewskia and M. Pakiet. *Application and Characterization of Surfactants*, ed. R. Najjar, *IntechOpen*, 2017, ch. 4, p. 97.

9 (a) M. Damen, A. J. J. Groenen, S. F. M. van Dongen, R. J. M. Nolte, B. J. Scholte and M. C. Feiters, *Med. Chem. Commun.*, 2018, 9, 1404; (b) M. Martínez-Negro, K. Kumar, A. L. Barrán-Berdón, S. Datta, F. Kondaiah, E. Junquera, S. Bhattacharya and E. Aicart, *ACS Appl. Mater. Interfaces*, 2016, 8, 22113; (c) M. Martínez-Negro, L. Blanco-Fernández, P. M. Tentori, L. Pérez, A. Pinazo, C. Tros de Ildaruya, E. Aicart and E. Junquera, *Nanomaterials*, 2018, 8, 1061.

10 L. Gallego-Yerga, M. Lomazzetti, V. Franceschini, F. Sansone, C. Ortiz Mellet, G. Donofrio, A. Casnati and J. M. García Fernández, *Org. Biomol. Chem.*, 2015, 13, 1708.

11 I. Pflueger, C. Charrat, C. Ortiz Mellet, J. M. García Fernández, C. Di Giorgio and J. M. Benito, *Org. Biomol. Chem.*, 2016, 14, 10037.

12 M. Al-Dulaymi, D. Michel, J. M. Chitanda, A. El-Aneed, R. E. Verrall, P. Grochulski and I. Badea, *Bioconjugate Chem.*, 2018, 29, 3293.

13 R. Ni, J. Zhou, N. Hossain and Y. Chau, *Adv. Drug Delivery Rev.*, 2016, 106, 3.

14 L. Zhang, P. Wang, Q. Feng, N. Wang, Z. Chen, Y. Huang, W. Zheng and X. Jiang, *NPG Asia Mater.*, 2017, 9, e441.

15 R. V. Benjaminsen, M. A. Mattebjer, J. R. Henriksen, S. M. Moghimi and T. L. Andreasen, *Mol. Ther.*, 2013, 21, 149.

16 (a) B. Abdallah, A. Hassan, C. Benoist, D. Goula, J. P. Behr and B. A. Demeneix, *Hum. Gene Ther.*, 1996, 7, 1947; (b) Y. Wang, M. Ye, R. Xie and S. Gong, *Bioconjugate Chem.*, 2019, 30, 325.

17 T. Bus, A. Traeger and U. S. Schubert, *J. Mater. Chem. B*, 2018, 6, 6904.

18 M. Martínez-Negro, G. Caracciolo, S. Palchetti, D. Pozzi, A. L. Capriotti, C. Cavaliere, A. Lagana, C. Ortiz Mellet, J. M. Benito, J. M. García Fernández, E. Aicart and E. Junquera, *Biochim. Biophys. Acta, Gen. Subj.*, 2017, 1861, 1737.

19 X. Liu, X. Gao, S. Zheng, B. Wang, Y. Li, C. Zhao, Y. Muftuoglu, S. Chen, Y. Li, H. Yao, H. Sun, Q. Mao, C. You, G. Guo and Y. Wei, *Nanomedicine*, 2017, 13, 1993.

20 K. Minami, K. Okamoto, K. Doi, K. Harano, E. Noiri and E. Nakamura, *Sci. Rep.*, 2014, 4, 4916.